bluuebunny/crossref_metadata_2025_split huggingface dataset:
Risk factors and outcomes with surgical bioprosthetic mitral valve dysfunction
Authors: Gwak Seo-Yeon , Ko Kyu-Yong , Cho Iksung , Hong Geu-Ru , Ha Jong-Won , Shim Chi Young 
Published: September 2022

BackgroundThere are insufficient data regarding the risk factors associated with valve dysfunction of bioprosthetic valves in the mitral position This study aimed to investigate the factors associated with bioprosthetic mitral valve (MV) dysfunction (MVD).MethodsA total of 245 patients (age 67.2±11.2 years, 74.9% women) who were followed up for more than 5 years after surgical bioprosthetic MV replacement were analysed in the setting of retrospective study design. MVD was defined as an increased mean gradient of >5 mm Hg with limited leaflet motion and/or newly developed MV regurgitation of at least moderate severity on follow-up echocardiography. The clinical outcome was defined as a composite of cardiovascular mortality, redo MV surgery or intervention and heart failure-related hospitalisations.ResultsDuring a median of 96.0 months (IQR 67.0–125.0 months), bioprosthetic MVD occurred in 66 (27.6%) patients. Factors associated with bioprosthetic MVD detected by multivariate regression analysis were age at surgery (HR 0.98, 95% CI 0.96 to 0.99, p<0.001), chronic kidney disease (HR 3.27, 95% CI 1.74 to 6.12, p<0.001), elevated mean diastolic pressure gradient >5.5 mm Hg across the bioprosthetic MV early after operation (HR 2.02, 95% CI 1.08 to 3.78, p=0.028) and average haemoglobin level after surgery (HR 0.80, 95% CI 0.67 to 0.96, p=0.015). Patients with bioprosthetic MVD showed significantly poorer clinical outcomes than those without bioprosthetic MVD (log-rank p<0.001).ConclusionsYoung age at operation, chronic kidney disease, elevated pressure gradient across the bioprosthetic MV early after surgery and postsurgical anaemia are associated with bioprosthetic MVD. Bioprosthetic MVD is associated with poor clinical outcomes.
Driving chiral phase transition with ring diagram
Authors: Lo Pok Man , Szymański Michał , Redlich Krzysztof , Sasaki Chihiro 
Published: September 2022

AbstractWe study the dressing of four-quark interaction by the ring diagram, and its feeding back to the quark gap equation, in an effective chiral quark model. Implementing such an in-medium coupling naturally reduces the chiral transition temperature in a class of chiral models, and is capable of generating the inverse magnetic catalysis at finite temperatures. We also demonstrate the important role of confining forces, via the Polyakov loop, in a positive feedback mechanism which reinforces the inverse magnetic catalysis.
The applicability of hydrodynamics in heavy ion collisions at $$\sqrt{s_\mathrm{NN}}$$ = 2.4–7.7 GeV
Authors: Inghirami Gabriele , Elfner Hannah 
Published: September 2022

AbstractTo assess the degree of equilibration of the matter created in heavy-ion reactions at low to intermediate beam energies, a hadronic transport approach (SMASH) is employed. By using a coarse-graining method, we compute the energy momentum tensor of the system at fixed time steps and evaluate the degree of isotropy of the diagonal terms and the relative magnitude of the off-diagonal terms. This study focuses mostly on Au+Au collisions in the energy range $${\sqrt{s}_\mathrm{NN}}$$

s

NN

= 2.4–7.7 GeV, but central collisions of lighter ions like C+C, Ar+KCl and Ag+Ag are considered as well. We find that the conditions concerning local equilibration for a hydrodynamic description are reasonably satisfied in a large portion of the system for a significant amount of time (several fm/c) when considering the average evolution of many events, yet they are rarely fulfilled on an event by event basis. This is relevant for the application of hybrid approaches at low beam energies as they are or will be reached by the HADES experiment at GSI, the future CBM experiment at FAIR as well as the beam energy scan program at RHIC.
D-meson production in high energy pA collisions within the QCD color dipole transverse momentum representation
Authors: dos Santos G. Sampaio , Machado M. V. T. , Gil da Silveira G. 
Published: September 2022

AbstractThe D-meson production is investigated by considering the unintegrated gluon distribution within the dipole approach in the momentum representation. We analyze the D-meson spectrum accounting for the effects of nonlinear behavior of the QCD dynamics which can be accordingly addressed in the dipole framework. The unintegrated gluon distribution is obtained by using geometric scaling property and the results are compared to the Glauber–Gribov framework. The absolute transverse momentum spectra and the nuclear modification ratios are investigated. Predictions are compared with the experimental measurements by the ALICE and LHCb Collaborations in pA collisions for different rapidity bins.
Leptons lurking in semi-visible jets at the LHC
Authors: Cazzaniga Cesare , de Cosa Annapaola 
Published: September 2022

AbstractThis Letter proposes a new search for confining dark sectors at the Large Hadron Collider. As a result of the strong dynamics in the hidden sector, dark matter could manifest in proton-proton collisions at the Large Hadron Collider in form of hadronic jets containing stable invisible bound states. These semi-visible jets have been studied theoretically and experimentally in the fully hadronic signature where the unstable composite dark matter can only decay promptly back to Standard Model quarks. We present a simplified model based on two messenger fields separated by a large mass gap allowing dark bound states to decay into pairs of oppositely charged leptons. The resulting experimental signature is characterized by non-isolated lepton pairs inside semi-visible jets. We propose a search strategy independent from the underlying model assumptions targeting this new signature, and discuss the orthogonality with respect to the existing searches. Remaining agnostic on the shape of the di-lepton spectrum, we determine the sensitivity of a dedicated analysis to the target signal. The proposed search can claim the $$3 \sigma $$

3
σ

evidence (exclusion) of the heavier mediator up to masses of 3.5 TeV (4.5 TeV) with the full Run 2 data of the LHC. Exploiting the resonant feature of the lepton pairs can enhance the sensitivity reach on a specific model. We estimate that an analysis using the di-lepton invariant mass information can reach $$5 \sigma $$

5
σ

discovery up to masses of 3.5 TeV and improve the exclusion up to more than 5 TeV.
A POLYOSTIC FORM OF FIBROUS DYSPLASIA: CORRECTION OF THE SHORTENED AND DEFORMED RIGHT UPPER LIMB WITH TSF EXTERNAL FIXATOR SYSTEM– CASE REPORT
Authors: Megremis Panos K. , Megremis Orestis P. 
Published: September 2022

Fibrous dysplasia (FD) is a congenital skeletal disorder characterized by the replacement of the bone marrow with fibrous tissue. FD may occur in isolation or association with endocrinopathies, and in that case, labeled McCune–Albright syndrome (MAS). FD can cause bone deformities or/and limb length discrepancies. The surgical intervention aims to correct limb deformities and length discrepancies while improving regional aesthetics. We report a case of a 14-year-old girl with FD that had affected her upper limbs. More characteristic had been the shortening of the right humerus (10 cm discrepancy from the left humerus) and the gun-stock deformity of the elbow. On the X-ray, a prominent feature was the shortening of the humerus and the valgus deformity of its distal end. The lengthening and correction of the deformity of the right humerus had been performed using the Taylor spatial frame (TSF) system. The software program had provided us with the estimated minimum correction time of 143 days for 7 cm humeral lengthening. A total of 157 days had been needed to lengthen and correct the deformity. The TSF system allows the simultaneous lengthening and correction of all the components of a multiplanar malformation of a limb and minimizes the required time.
AppClassNet
Authors: Wang Chao , Finamore Alessandro , Yang Lixuan , Fauvel Kevin , Rossi Dario 
Published: September 2022

The recent success of Artificial Intelligence (AI) is rooted into several concomitant factors, namely theoretical progress coupled with abundance of data and computing power. Large companies can take advantage of a deluge of data, typically withhold from the research community due to privacy or business sensitivity concerns, and this is particularly true for networking data. Therefore, the lack of high quality data is often recognized as one of the main factors currently limiting networking research from fully leveraging AI methodologies potential.
Following numerous requests we received from the scientific community, we release AppClassNet, a commercial-grade dataset for benchmarking traffic classification and management methodologies. AppClassNet is significantly larger than the datasets generally available to the academic community in terms of both the number of samples and classes, and reaches scales similar to the popular ImageNet dataset commonly used in computer vision literature. To avoid leaking user- and business-sensitive information, we opportunely anonymized the dataset, while empirically showing that it still represents a relevant benchmark for algorithmic research. In this paper, we describe the public dataset and our anonymization process. We hope that AppClassNet can be instrumental for other researchers to address more complex commercial-grade problems in the broad field of traffic classification and management.
Sleep Patterns and Risk of Prostate Cancer: A Population-Based Case Control Study in France (EPICAP)
Authors: Cordina-Duverger Emilie , Cénée Sylvie , Trétarre Brigitte , Rebillard Xavier , Lamy Pierre-Jean , Wendeu-Foyet Gaelle , Menegaux Florence 
Published: September 2022

Abstract

Background:
Sleep disturbances have been singled out for their implication in the risk of several cancer sites. However, results for prostate cancer are still inconsistent.

Methods:
We used data from the EPICAP study, a French population-based case–control study including 819 incident prostate cancer cases and 879 controls frequency matched by age. Detailed information on sleep duration on work/free days, and sleep medication over lifetime was collected.

Results:
Sleep duration and sleep deprivation were not associated with prostate cancer, whatever the aggressiveness of prostate cancer. However, sleep deprivation was associated with an increased prostate cancer risk among men with an evening chronotype [OR, 1.96; 95% confidence interval (CI), 1.04–3.70]. We also observed an increased risk of prostate cancer with higher duration of sleep medication use (Ptrend = 0.008). This association with long duration of sleep medication use (≥10 years) was more pronounced among men who worked at night 15 years or more (OR, 3.84; 95% CI, 1.30–11.4) and among nonusers of NSAID (OR, 2.08; 95% CI, 1.15–3.75).

Conclusions:
Our results suggested that chronotype, night work, or NSAID use could modify the association between sleep disorders and prostate cancer occurrence needing further investigations to go further.

Impact:
EPICAP is the first study, which investigates several sleep indicators taking into account potential effect modifiers. If our findings were confirmed, we could identify subgroups of men at higher risk of prostate cancer that may be accessible to preventive measures.
Plasma CD27, a Surrogate of the Intratumoral CD27–CD70 Interaction, Correlates with Immunotherapy Resistance in Renal Cell Carcinoma
Authors: Benhamouda Nadine , Sam Ikuan , Epaillard Nicolas , Gey Alain , Phan Letuan , Pham Hang Phuong , Gruel Nadège , Saldmann Antonin , Pineau Joséphine , Hasan Milena , Quiniou Valentin , Nevoret Camille , Verkarre Virginie , Libri Valentina , Mella Sebastien , Granier Clémence , Broudin Chloe , Ravel Patrice , De Guillebon Eléonore , Mauge Laetitia , Helley Dominique , Jabla Bernd , Chaput Nathalie , Albiges Laurence , Katsahian Sandrine , Adam Julien , Mejean Arnaud , Adotevi Olivier , Vano Yann A. , Oudard Stéphane , Tartour Eric 
Published: September 2022

AbstractPurpose:CD70 is a costimulatory molecule known to activate CD27-expressing T cells. CD27–CD70 interaction leads to the release of soluble CD27 (sCD27). Clear-cell renal cell carcinoma (ccRCC) expresses the highest levels of CD70 among all solid tumors; however, the clinical consequences of CD70 expression remain unclear.Experimental Design:Tumor tissue from 25 patients with ccRCC was assessed for the expression of CD27 and CD70 in situ using multiplex immunofluorescence. CD27+ T-cell phenotypes in tumors were analyzed by flow cytometry and their gene expression profile were analyzed by single-cell RNA sequencing then confirmed with public data. Baseline sCD27 was measured in 81 patients with renal cell carcinoma (RCC) treated with immunotherapy (35 for training cohort and 46 for validation cohort).Results:In the tumor microenvironment, CD27+ T cells interacted with CD70-expressing tumor cells. Compared with CD27− T cells, CD27+ T cells exhibited an apoptotic and dysfunctional signature. In patients with RCC, the intratumoral CD27–CD70 interaction was significantly correlated with the plasma sCD27 concentration. High sCD27 levels predicted poor overall survival in patients with RCC treated with anti–programmed cell death protein 1 in both the training and validation cohorts but not in patients treated with antiangiogenic therapy.Conclusions:In conclusion, we demonstrated that sCD27, a surrogate marker of T-cell dysfunction, is a predictive biomarker of resistance to immunotherapy in RCC. Given the frequent expression of CD70 and CD27 in solid tumors, our findings may be extended to other tumors.
An Ex Vivo Organotypic Culture Platform for Functional Interrogation of Human Appendiceal Cancer Reveals a Prominent and Heterogenous Immunological Landscape
Authors: Weitz Jonathan , Hurtado de Mendoza Tatiana , Tiriac Herve , Lee James , Sun Siming , Garg Bharti , Patel Jay , Li Kevin , Baumgartner Joel , Kelly Kaitlin J. , Veerapong Jula , Hosseini Mojgan , Chen Yuan , Lowy Andrew M. 
Published: September 2022

Abstract

Purpose:
Epithelial neoplasms of the appendix are difficult to study preclinically given their low incidence, frequent mucinous histology, and absence of a comparable organ in mice for disease modeling. Although surgery is an effective treatment for localized disease, metastatic disease has a poor prognosis as existing therapeutics borrowed from colorectal cancer have limited efficacy. Recent studies reveal that appendiceal cancer has a genomic landscape distinct from colorectal cancer and thus preclinical models to study this disease are a significant unmet need.

Experimental Design:
We adopted an ex vivo slice model that permits the study of cellular interactions within the tumor microenvironment. Mucinous carcinomatosis peritonei specimens obtained at surgical resection were cutoff using a vibratome to make 150-μm slices cultured in media.

Results:
Slice cultures were viable and maintained their cellular composition regarding the proportion of epithelial, immune cells, and fibroblasts over 7 days. Within donor specimens, we identified a prominent and diverse immune landscape and calcium imaging confirmed that immune cells were functional for 7 days. Given the diverse immune landscape, we treated slices with TAK981, an inhibitor of SUMOylation with known immunomodulatory functions, in early-phase clinical trials. In 5 of 6 donor samples, TAK981-treated slices cultures had reduced viability, and regulatory T cells (Treg). These data were consistent with TAK981 activity in purified Tregs using an in vitro murine model.

Conclusions:
This study demonstrates an approach to study appendiceal cancer therapeutics and pathobiology in a preclinical setting. These methods may be broadly applicable to the study of other malignancies.
Abstract IA26: Understanding CLL and Richter’s syndrome biology through mouse models of human genetics
Authors: ten Hacken Elisa 
Published: September 2022

Abstract
Large-scale human next generation sequencing studies have progressively defined the complex genetic landscape of chronic lymphocytic leukemia (CLL) and Richter’s syndrome (RS), yet the difficulties in rapid manipulation of primary CLL cells and the limited availability of cell lines have challenged studies aimed at interrogating the function of the so-called disease “drivers”, defined in human studies through statistical inference. Mouse models represent powerful tools to study mechanisms of normal and malignant B cell biology. Conditional knock-in/knock-out systems have allowed B-cell restricted modeling of CLL genetic lesions, with MDR mice being the first example of a genetically-faithful CLL model, recapitulating the most common genomic aberration of human disease, del(13q). Since then, a series of models generated by our group and others have allowed to uncover key functional changes underlying disease onset and transformation, including in the context of combined mutation in the splicing factor Sf3b1 and the DNA damage response gene Atm, sole mutation in the B cell developmental factor Ikzf3, the nuclear export receptor Xpo1, the ribosomal protein Rps15, and the DNA methyltransferase Dnmt3a (the latter not a CLL lesion per se, but recapitulating disordered methylation patterns typical of CLL). The CRISPR-Cas9 gene editing technology has further enabled B-cell restricted introduction of multiple combinatorial loss-of-function lesions, allowing the generation of faithful models not only of CLL but, importantly, of transformation into RS. In this presentation, I will describe the application of mouse models to studies of CLL and RS pathogenesis and treatment, with a focus on key aspects uncovered through the characterization of genetically- inspired mouse lines of recurrent disease drivers. I will provide a perspective on how these novel models combined with new technology allowed the dissection of mechanisms of disease evolution and response to therapy with greater depth than previously possible, representing valuable platforms for functional genomic analyses.
Citation Format: Elisa ten Hacken. Understanding CLL and Richter’s syndrome biology through mouse models of human genetics [abstract]. In: Proceedings of the Third AACR International Meeting: Advances in Malignant Lymphoma: Maximizing the Basic-Translational Interface for Clinical Application; 2022 Jun 23-26; Boston, MA. Philadelphia (PA): AACR; Blood Cancer Discov 2022;3(5_Suppl):Abstract nr IA26.
Abstract IA31: A multi-scale, multiomic atlas of human and follicular lymphoma lymph nodes
Authors: Radtke Andrea J. 
Published: September 2022

Abstract
Reference atlases, molecular and spatial maps of mammalian tissues, are critical resources for discovery efforts and translational research. Their utility is dependent on operationalizing the resulting data by identifying cell types, histological patterns, and predictive biomarkers underlying health and disease. The human lymph node (LN) offers a compelling use case because of its importance in immunity, structural and cellular diversity, and neoplastic involvement. One hematological malignancy, follicular lymphoma (FL), evolves from developmentally blocked germinal center B cells residing in and trafficking through these tissues. To promote survival and immune escape, tumor B cells undergo significant genetic changes and extensively remodel the lymphoid microenvironment. Here, we present an integrated portrait of healthy and FL LNs using multiple genomic and advanced imaging technologies. By leveraging the strengths of each platform, we identified several tumor-specific features and microenvironmental patterns enriched in individuals who experience early relapse, the most high-risk of FL patients.
Citation Format: Andrea J. Radtke. A multi-scale, multiomic atlas of human and follicular lymphoma lymph nodes [abstract]. In: Proceedings of the Third AACR International Meeting: Advances in Malignant Lymphoma: Maximizing the Basic-Translational Interface for Clinical Application; 2022 Jun 23-26; Boston, MA. Philadelphia (PA): AACR; Blood Cancer Discov 2022;3(5_Suppl):Abstract nr IA31.
Does a History of Cancer Influence the Effectiveness of Statins on Outcomes After Stroke?
Authors: Olaiya Muideen T. , Andrew Nadine E. , Dalli Lachlan L. , Ung David , Kim Joosup , Sundararajan Vijaya , Cadilhac Dominique A. , Thrift Amanda G. , Nelson Mark R. , Churilov Leonid , Kilkenny Monique F. ,   on behalf of PRECISE Investigators
Published: September 2022

Background:
Evidence is growing on anticancer effects of statins. We investigated whether the effectiveness of treatment with statins after ischemic stroke on mortality is influenced by a history of cancer.

Methods:
Analyses of 90-day survivors of ischemic stroke (2012–2016; 45 hospitals) using linked registry and administrative data. Dispense of statins within 90 days postdischarge was determined from pharmaceutical records. Participants were followed from 91 days postdischarge until death or June 30, 2018. History of cancer was determined from hospital data. Propensity score–adjusted Cox proportional hazards regression model was used to determine the association between being dispensed statins and survival. The influence of history of cancer on this association was assessed based on the concepts of (1) statistical interaction and (2) biological interaction using 3 indices: relative excess risk due to interaction>0, attributable proportion due to interaction >0, or synergy index >1.

Results:

Among 9948 eligible participants (median age=72 years, 42% female), there were 1463 deaths. In adjusted analyses, there was no statistical interaction between being dispensed statins and history of cancer on mortality (
P
=0.156). However, being dispensed statins had a significant positive biological interaction with having a history of cancer on mortality: relative excess risk due to interaction, 2.80 (95% CI, 1.56–5.05), attributable proportion due to interaction, 0.45 (95% CI, 0.23–0.66), and synergy index, 2.14 (95% CI, 1.32–3.49).

Conclusions:
Treatment with statins after ischemic stroke may confer additional survival benefits for people who also have had cancer.
The Neoliberal State and Management of the Covid-19 Pandemic in Nigeria
Authors: Okolie Aloysius-Michaels , Nnamani Kelechi Elijah , Ononogbu Olihe Adaeze , Nwoke Ikemefuna Sunday , Nzekwe Florence Ifeoma , Ike Chinedu Cyril , Ngoka Ruth Obioma , Okoro Chinonso Akudo , Ekwu Hope Olilanya 
Published: September 2022

Abstract
This study examines how neoliberalism affected the management of Covid-19 in Nigeria. As a result of its emphasis on privatisation and austerity, neoliberalism discouraged social investment programmes and provisioning. The privatisation of Nigeria’s health sector severely stifled health financing, which led to the collapse of public health institutions and the proliferation of private and informal health delivery systems. It limited universal access to quality healthcare, worsened the health conditions of poor Nigerians and rendered the health sector incapable of managing emergency health situations, such as Covid-19. The absence of well-coordinated social investment programmes to cushion the effects of lockdown widened social inequality and misery, making it impossible for citizens in the informal economy to adhere to the Covid-19 guidelines. The state responded with repression to enforce the rules. This study recommends overhauling the Nigerian state and its political economy as a condition for reducing citizen’s vulnerability to a pandemic.